Pharmaceutical Executive: October 2025

View the Pharmaceutical Executive October 2025 issue in an interactive format.

Featured among the coverage slate in the October issue of Pharmaceutical Executive are deep dives into the long-term implications of new policy-driven overhauls in drug pricing.

Cencora CEO Bob Mauch discusses the lessons learned during his first year at the helm—and tackling a complex future for pharma distribution.

An analysis of pricing data for 12 high-revenue drugs from Medicare Part B and Part D compares US wholesale acquisition costs with the lowest prices in reference countries under the most-favored nation model.

Amid converging pharma pricing trends, such as those triggered by the Inflation Reduction Act, companies must adopt novel operational practices and strategic approaches in line with new parameters for success across a product’s lifecycle.

A blueprint for how companies can move from isolated pilots toward effective AI implementation.

The importance for pharma in recognizing integrated data sources as necessary infrastructure—not just a competitive edge.

Tips for turning transactional outreach into a trusted working relationship.

A case study in leading and guiding a cultural reset and strategic revival.

How cell and gene therapy developers can lessen the chances of receiving FDA complete response letters through the use of proactive chemistry, manufacturing, and controls strategies.